The Gateway to Your Orthopaedic Recovery.

Author listing

Meet our authors and contributors and explore their latest articles, insights, and expertise
Editor-in-Chief

Editor-in-Chief 's Latest Stories

Condition : Osteoarthritis Interventions : Drug: viscosupplementation 1+1+1; Drug: viscosupplementation 3 at once Sponsors : University of Sao Paulo General Hospital; University of Sao Paulo General H...
Condition : Knee Osteoarthritis Intervention : Device: iUni G2+ Sponsor : ConforMIS, Inc. Recruiting - verified November 2013
Condition : Psoriatic Arthritis Interventions : Dietary Supplement: n-3PUFA; Dietary Supplement: olive oil Sponsor : Aalborg Universityhospital Recruiting - verified January 2014
Condition : Osteoarthritis Intervention : Procedure: treatment with A3 SVF Sponsors : Institute of Regenerative and Cellular Medicine; Institute of Regenerative and Cellular Medicine Recruiting - veri...
Condition : Knee Osteoarthritis Interventions : Device: Zimmer; Device: Stryker Sponsors : Duke University; Duke University Recruiting - verified September 2013
Condition : Osteoarthritis Interventions : Procedure: articular lavage with saline injection; Drug: 1 ampoule of Hylan GF-20; Drug: 2 ampoules of Hylan GF-20; Drug: 3 ampoules of Hylan GF-20 Sponsors...
Two injections in total and 3 ml autologous adipose-tissue-derived progenitor cells(haMPCs) for each injection; time-points for intervention: 1) initial injection; 2) 3 weeks following initial injecti...
This is a Phase 3 extension study to assess the long-term efficacy and safety of lesinurad in combination with allopurinol in subjects who completed the double-blind treatment period in Studies RDEA59...
This is a Phase 3 extension study to assess the long-term efficacy and safety of lesinurad in combination with febuxostat in subjects who completed the double-blind treatment period in Study RDEA594-3...
This is a Phase 3 extension study to assess the long-term efficacy and safety of lesinurad in combination with allopurinol in subjects who completed the double-blind treatment period in Studies RDEA59...